Palmitoyl Dipeptide-6 vs Chonluten
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Palmitoyl Dipeptide-6Anti-Aging & Longevity
Chonluten- Summary
- Palmitoyl Dipeptide-6 is a synthetic dipeptide (lysine-threonine) with a palmitoyl fatty acid tail, designed to penetrate the skin barrier and stimulate the extracellular matrix components essential for skin firmness. It activates fibronectin and type IV collagen synthesis, improving skin density and firmness particularly in mature or sagging skin.
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Half-Life
- Not applicable (topical)
- Short (minutes for the peptide); sustained gene-regulatory effects
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.005–0.05% in formulation
- 10 mg per day
- Frequency
- Once or twice daily
- Daily for 10–30 days
- Key Benefits
- Increases skin firmness and density
- Stimulates fibronectin and collagen IV production
- Strengthens the dermal-epidermal junction
- Reduces skin sagging in mature skin
- Improves skin texture and smoothness
- Supports extracellular matrix integrity
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Side Effects
- Generally well-tolerated
- Rare mild skin irritation in sensitive individuals
- No known systemic effects at cosmetic concentrations
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Stacks With
- —
- —